Abstract 294: Comparative biochemical kinase activity analysis identifies lirafugratinib as a highly selective FGFR2 inhibitor.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7148629675
Cites:
Cited by:
Related to: